Tumor-associated antigens on hepatocellular carcinoma cells (HCC TAAs) (HCC TAAs)

Tumor-associated antigens (TAAs) on hepatocellular carcinoma (HCC) cells are a diverse group of proteins and glycoproteins that are either uniquely expressed or significantly overexpressed in malignant liver cells compared to healthy tissue (Source: NIH). These antigens include oncofetal proteins like Alpha-fetoprotein (AFP) and Glypican-3 (GPC3), as well as cancer-testis antigens such as MAGE-A and NY-ESO-1 (Source: PubMed). Biologically, these molecules often play roles in fetal development, cell proliferation, and the suppression of immune responses within the tumor microenvironment (Source: Nature Reviews Gastroenterology & Hepatology). In the context of HCC, TAAs serve as critical targets for various therapeutic strategies, including monoclonal antibodies, chimeric antigen receptor (CAR) T-cell therapies, and cancer vaccines (Source: Journal of Hepatology). Drugs like codrituzumab target GPC3 to induce antibody-dependent cellular cytotoxicity, while AFP levels are used to select patients for therapies like ramucirumab (Source: FDA). However, the heterogeneity of TAA expression across different HCC nodules and the risk of on-target, off-tumor toxicity remain significant challenges in clinical development (Source: Lancet Oncology). These antigens are also vital for diagnostic and prognostic purposes, with AFP being the most commonly utilized biomarker in clinical practice (Source: AASLD). Emerging therapies continue to explore multi-antigen targeting to overcome the limitations of tumor escape mechanisms (Source: Cancer Discovery).

Other names

HCC-associated antigensHepatoma-associated antigensLiver cancer antigensHepatocellular carcinoma antigens

Immunotherapeutic targeting via antibody-dependent cellular cytotoxicity (ADCC), chimeric antigen receptor (CAR) T-cell mediated lysis, and vaccine-induced cytotoxic T-lymphocyte (CTL) activation (Source: PubMed, NIH).